Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-nCoV Immunogenicity Bridging and Lot Consistency Study
NCT04916886Phase 4Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ad5-ncov in coronavirus disease 2019 (COVID-19), sponsored by CanSino Biologics Inc. Primary endpoint: Geometric Mean Titer of anti-SARS-CoV-2 specific neutralizing antibody at 28 days. Started Jun 2021; status: completed.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04916886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916886.